Skip to main content

Table 2 Exploratory analysis of prognostic factors for PFS

From: Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer

Covariates

Univariate analysis

Multivariate analysis

HR (95% CI)

P

HR (95% CI)

P

Number of prior therapies

≥4

1.37 (0.73–2.56)

0.324

  

Sex

male

0.65 (0.31–1.37)

0.261

  

Age

> 66

0.97 (0.53–1.76)

0.931

  

ECOG PS

2

1.57 (0.72–3.41)

0.251

  

Location of primary tumor

Stomach

0.59 (0.35–1.37)

0.222

  

Histology

diffuse

0.85 (0.44–1.63)

0.636

  

HER2 overexpression

(+)

1.52 (0.80–2.87)

0.192

  

Concomitant use of NSAIDs / antiplatelets / anticoagulation therapy

(+)

1.12 (0.60–2.11)

0.709

  

History of hypertension

(+)

0.53 (0.27–1.04)

0.066

  

Number of metastatic sites

≥2

1.51 (0.83–2.75)

0.17

  

Ascites

(+)

1.78 (0.97–3.26)

0.061

  

Peritoneal metastasis

(+)

1.32 (0.74–2.37)

0.339

  

Previous gastrectomy

(+)

0.48 (0.26–0.89)

0.019

0.50 (0.27–0.94)

0.031

Time from initiation of 1st line therapy

≥2 years

0.53 (0.29–0.98)

0.043

0.66 (0.35–1.25)

0.208

Prior history of ICI

(+)

1.03 (0.52–2.06)

0.92

  

ALP

≥WNL

1.08 (0.59–1.98)

0.797

  

CRP

≥WNL

1.34 (0.71–2.51)

0.359

  

LDH

≥WNL

1.42 (0.74–2.74)

0.285

  

NLR

< 2.5

0.35 (0.16–0.74)

0.002

0.38 (0.17–0.87)

0.017

PLR

< 250

0.58 (0.32–0.97)

0.033

0.83 (0.44–1.56)

0.413

  1. Abbreviations: PFS progression-free survival, HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, NSAIDs nonsteroidal anti-inflammatory drugs, ICI immune checkpoint inhibitor, ALP alkaline phosphatase, CRP C-reactive protein, LDH lactate dehydrogenase, WNL within normal limits